Loading clinical trials...
Loading clinical trials...
A Phase II Trial of Personalized Immunotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck That Have Progressed on Prior Immunotherapy
Conditions
Interventions
Nivolumab+Relatlimab
Nivolumab+Ipilimumab
Locations
1
United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Start Date
May 14, 2020
Primary Completion Date
August 12, 2023
Completion Date
August 12, 2024
Last Updated
January 8, 2026
NCT05075980
NCT05815927
NCT06736379
NCT05329532
NCT05059444
NCT06823479
Lead Sponsor
Dan Zandberg
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions